NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
Q-Line Biotech

Q-Line Biotech

IPO
Issue: 214.48 CrPrice: ₹ 326.00
View Details

Q-Line Biotech IPO Allotment to be Finalized on 26 May

The allotment of Q-Line Biotech IPO, which opened for subscription on 21 May and closed on 25 May, is set to be finalized on Tuesday, 26 May. The shares of Q-Line Biotech IPO will make their debut on the National Stock Exchange (NSE) Small and Medium Enterprises (SME) platform on 29 May.

Q-Line Biotech is a company engaged in the development, manufacturing, and marketing of reagents, including kits, point-of-care (POC) devices, and consumables. The company also manufactures and distributes diagnostic equipment catering to healthcare diagnostic requirements. Its major manufacturing segments comprise indigenous production of reagents across haematology, clinical chemistry, immunodiagnostics, molecular diagnostics, and other categories such as POC devices and rapid tests, as well as the manufacturing and supply of in-vitro diagnostics (IVD), pathology equipment, and related devices.

Grey Market Premium

Read also: SMR Jewels IPO Successfully Lists with Institutional Support

The shares of Q-Line Biotech IPO are commanding a strong premium in the grey market. According to Investorgain, the grey market premium (GMP) of Q-Line Biotech IPO is ₹115. This means that the estimated listing price of Q-Line Biotech IPO is likely to be ₹458, which is 33.53% higher than the IPO price of ₹343.

Allotment Status

The allotment of the Q-Line Biotech IPO is likely to be finalized on Tuesday, 26 May. Investors can check their allotment status on the NSE website or on the official allotment page of Purva Sharegistry (India) Pvt. Ltd, the registrar of the issue.

How to Check Allotment Status

Read also: Zepto Nears $1 Billion Quarterly Net Order Value Milestone Before IPO

To check the allotment status of the Q-Line Biotech IPO, investors can follow these steps:

  • Visit the NSE IPO status page.
  • Select "Equity & SME IPO bid details".
  • Choose "Q-Line Biotech" with the symbol "QLINE".
  • Enter your PAN number and application number.
  • Click on the "Submit" button.

Alternatively, investors can visit the official allotment page of Purva Sharegistry (India) and follow these steps:

  • Select 'Q-Line Biotech' from the IPO list.
  • Enter either your PAN number or application number.
  • Click on the 'Search' button.

IPO Details

The ₹214.48 crore IPO comprised solely a fresh issue of 62.53 lakh equity shares and did not include any offer-for-sale (OFS) portion. The proceeds from the issue will be utilized towards working capital needs, repayment of debt, and general corporate requirements. The IPO was priced in the range of ₹326–₹343 per share, with one lot comprising 400 shares. Retail investors were required to bid for a minimum of two lots, equivalent to 800 shares.

Subscription Status

The Q-Line Biotech IPO subscription status was 102 times on the last day. The retail portion was subscribed at 71.44x, the Non Institutional Investor (NII) portion was booked at 145.98x, and the Qualified Institutional Buyers (QIBs) portion received 123.94x bidding, according to Chittorgarh.

CategorySubscription Status
Retail Portion71.44x
Non Institutional Investor (NII) Portion145.98x
Qualified Institutional Buyers (QIBs) Portion123.94x

Investor Takeaway

Investors should be prepared for the potential listing of Q-Line Biotech IPO on NSE SME on 29 May.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.